The global cancer supportive care drugs market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing healthcare expenditure, large number of side effects of cancer treatment, accessibility to effective treatment methods such as tailored and target specific treatments, and growing adoption of biosimilars.
According to the International Agency for Research on Cancer (IARC) report, every year around 13 million people are diagnosed with cancer and 8 million death cases are recorded. The most leading cancer types are breast cancer and lung cancer with huge demand of supportive care drugs. Emerging countries such as India and China are encouraging destinations for market expansion. In these two countries increasing acceptance of biosimilar, low cost base, and beneficial healthcare reforms are aided the country based market.
There are some unmet needs present in cancer supportive care segment. Current treatment method gives symptomatic relief only. In this market effective analgesic drugs with lower risk of acceptance and misuse is major area of unmet need. At preset around 10 products are going through clinical trials to treat different side effects of cancer therapy.
Many major market players are working on identifying new targets, addressing unmet needs, and certainly developing stronger drug pipelines. Tanezumab and Rolontis are leading pipeline drugs which are anticipated to be launched over the forecast period. These drugs uses developed drug delivery technologies for efficient result and lesser adverse side-effects.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of cancer and growing disposable income are projected to fuel the market growth in coming years.
- Rising number of patients suffering from the effects of anti-cancer therapies and increasing awareness among propel are anticipated to propel the market growth.
- Increasing developments in infrastructure of healthcare and rising governments and non-government initiatives are expected to boost the market expansion over the forecast period.
- Increasing technological advancements in targeted therapy drugs along with growing adoption of these drugs in which side effects are lesser than traditional therapy drugs are anticipated to drive the growth of the market.
- Several side effects related to cancer supportive care drugs is projected to hamper the market expansion over the forecast period.
- Stringent regulations is anticipated to impede the growth of the market in coming years.
Scope of Cancer Supportive Care Drugs Market Report
The report on the global cancer supportive care drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Cancer Supportive Care Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Therapeutic Classes (Granulocyte-Colony Stimulating Factors, Bisphosphonates, Anti-emetics, Opioids, Nonsteroidal Anti-Inflammatory Drug, and Erythropoiesis Stimulating Agents)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Amgen Inc., Johnson & Johnson, Merck, F. Hoffmann-La Roche AG, Helsinn Healthcare SA, Heron Therapeutics, Inc., Tesaro, Sandoz, Hospira, Teva Pharmaceuticals Industries Ltd., 3SBio, and BioSidus
|
Cancer Supportive Care Drugs Market Segment Insights
Granulocyte-colony stimulating factors segment is projected to hold a key market share
Based on therapeutic classes, the cancer supportive care drugs market is segmented into granulocyte-colony stimulating factors (G-CSFs), bisphosphonates, anti-emetics, opioids, nonsteroidal anti-inflammatory drug (NSAIDs), and erythropoiesis stimulating agents (ESAs). Majorly G-CSFs is used for the treatment of neutropenia (CIN), bisphosphonates for cancer induced bone diseases, antiemetics for nausea and vomiting (CINV), opioids and NSAIDs for treatment of cancer pain, and ESAs for Anemia (CIA).
The G-CSFs segment is expected to hold a key share of the market during the forecast period. The granulocyte stimulating factors including Neupogen and Neulasta held major market share followed by opioids. There are some brand which are prescribed in cancer supportive care, such as Merck’s Emend, Amgen’s Neupogen, Neulasta, Epogen and Xgeva, Helsinn’s Aloxi, Roche’s NeoRecormon, Heron’s Sustol, and Cinvanti. G-CSFs and ESAs have larger number of biosimilar products, which increased accessibility of affordable care for patients. The anti-emetics segment is projected to grow at a significant pace due to launch of new products.
Asia Pacific is expected to dominate the market
On the basis of regions, the cancer supportive care drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. In the U.S. less number of biosimilars were launched. But, penetration of biosimilar is projected to raise due to twice the average price of biologics
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to significant uptake of biosimilars. Growing prevalence of cancer and huge number of side-effects related to cancer treatment are expected to fuel the regional market growth. Availability of effective treatment methods, rising uptake of biosimilars, and increasing healthcare expenditure are some other factors propelling the market growth in this region.
Segments
The global cancer supportive care drugs market has been segmented on the basis of
Therapeutic Classes
- Granulocyte-colony Stimulating Factors (G-CSFs)
- Erythropoiesis Stimulating Agents (ESAs)
- Anti-emetics
- Bisphosphonates
- Opioids
- Nonsteroidal Anti-Inflammatory Drug (NSAIDs)
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the cancer supportive care drugs market are Amgen Inc., Johnson & Johnson, Merck, F. Hoffmann-La Roche AG, Helsinn Healthcare SA, Heron Therapeutics, Inc., Tesaro, Sandoz, Hospira, Teva Pharmaceuticals Industries Ltd., 3SBio, and BioSidus.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. Increasing biosimilar competition and expiration of patents impacted on many companies, majorly on Amgen Inc. and F. Hoffmann-La Roche AG.
Request For Customization
Enquiry Before Buying
Speak With Analyst
